Your browser doesn't support javascript.
loading
Estimating the delivery costs of COVID-19 vaccination using the COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool: the Lao People's Democratic Republic experience.
Yeung, Karene Hoi Ting; Kim, Eunkyoung; Yap, Wei Aun; Pathammavong, Chansay; Franzel, Lauren; Park, Yu Lee; Cowley, Peter; Griffiths, Ulla Kou; Hutubessy, Raymond Christiaan W.
Afiliação
  • Yeung KHT; Department of Immunization, Vaccines and Biologicals, World Health Organization, 20, Avenue Appia, 1211, Geneva 27, Switzerland.
  • Kim E; World Health Organization, Lao People's Democratic Republic, 125 Saphanthong Road, Unit5, Ban Saphanthongtai, Sisattanak District, P.O.Box 343, Vientiane Capital, Lao People's Democratic Republic.
  • Yap WA; Quanticlear Solutions Sdn. Bhd, Kuala Lumpur, Malaysia.
  • Pathammavong C; Mother and Child Health Center, National Immunization Programme, Ministry of Health, Vientiane Capital, Lao People's Democratic Republic.
  • Franzel L; Department of Immunization, Vaccines and Biologicals, World Health Organization, 20, Avenue Appia, 1211, Geneva 27, Switzerland.
  • Park YL; World Health Organization, Lao People's Democratic Republic, 125 Saphanthong Road, Unit5, Ban Saphanthongtai, Sisattanak District, P.O.Box 343, Vientiane Capital, Lao People's Democratic Republic.
  • Cowley P; Department of Health Governance and Financing, World Health Organization, 20, Avenue Appia, 1211, Geneva 27, Switzerland.
  • Griffiths UK; United Nations Children's Fund, 3 UN Plaza, New York, NY, 10017, USA.
  • Hutubessy RCW; Department of Immunization, Vaccines and Biologicals, World Health Organization, 20, Avenue Appia, 1211, Geneva 27, Switzerland. hutubessyr@who.int.
BMC Med ; 21(1): 248, 2023 07 10.
Article em En | MEDLINE | ID: mdl-37424001
ABSTRACT

BACKGROUND:

The COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool was developed to assist countries to estimate incremental financial costs to roll out COVID-19 vaccines. This article describes the purposes, assumptions and methods used in the CVIC tool and presents the estimated financial costs of delivering COVID-19 vaccines in the Lao People's Democratic Republic (Lao PDR).

METHODS:

From March to September 2021, a multidisciplinary team in Lao PDR was involved in the costing exercise of the National Deployment and Vaccination Plan for COVID-19 vaccines to develop potential scenarios and gather inputs using the CVIC tool. Financial costs of introducing COVID-19 vaccines for 3 years from 2021 to 2023 were projected from the government perspective. All costs were collected in 2021 Lao Kip and presented in United States dollar.

RESULTS:

From 2021 to 2023, the financial cost required to vaccinate all adults in Lao PDR with primary series of COVID-19 vaccines (1 dose for Ad26.COV2.S (recombinant) vaccine and 2 doses for the other vaccine products) is estimated to be US$6.44 million (excluding vaccine costs) and additionally US$1.44 million and US$1.62 million to include teenagers and children, respectively. These translate to financial costs of US$0.79-0.81 per dose, which decrease to US$0.6 when two boosters are introduced to the population. Capital and operational cold-chain costs contributed 15-34% and 15-24% of the total costs in all scenarios, respectively. 17-26% went to data management, monitoring and evaluation, and oversight, and 13-22% to vaccine delivery.

CONCLUSIONS:

With the CVIC tool, costs of five scenarios were estimated with different target population and booster dose use. These facilitated Lao PDR to refine their strategic planning for COVID-19 vaccine rollout and to decide on the level of external resources needed to mobilize and support outreach services. The results may further inform inputs in cost-effectiveness or cost-benefit analyses and potentially be applied and adjusted in similar low- and middle-income settings.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinação / Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Health_economic_evaluation Limite: Adolescent / Adult / Child / Humans País/Região como assunto: Asia Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinação / Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Health_economic_evaluation Limite: Adolescent / Adult / Child / Humans País/Região como assunto: Asia Idioma: En Revista: BMC Med Assunto da revista: MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça